Diagnostic (gallium GA 68 FAPi-46, PET/CT) for Stage I Pancreatic Cancer AJCC v8

Study Summary

This phase II trial tests whether 68Ga-FAPI-46 positron emission tomography (PET)/computed tomography (CT) scan works to image cancer-associated fibroblasts (CAFs) in patients with localized (has not spread to other parts of the body) pancreatic ductal adenocarcinoma (PDA). CAFs are a type of connective tissue cell that are found within or near cancerous tissue. Many CAFs express a protein called fibroblast activation protein (FAP) that are not found on healthy cells. 68Ga-FAPI-46 is a radioactive chemical compound designed to circulate through the body and attach itself to FAP on PDA cells. A PET/CT scan is then used to detect the location of FAP lesions. PET scans help to measure the information about functions of tissues and organs within the body. CT scans use X-rays to create images of the bones and internal organs within the body. Giving 68Ga-FAPI-46 PET/CT may help doctors improve upon the diagnosis and management of PDA.

Treatment Effectiveness

Trial Safety

Trial Design

Trial Logistics

Closest Location: Mayo Clinic in Rochester · Rochester, MN

2021First Recorded Clinical Trial

2 TrialsResearching Stage I Pancreatic Cancer AJCC v8

502 CompletedClinical Trials

Eligibility Criteria

About The Reviewer

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.